Holen Sie sich die Stockscreener-App
105.95
5.90%
-6.64
Schlusskurs vom Vortag:
$112.59
Offen:
$113.25
24-Stunden-Volumen:
558.51K
Relative Volume:
0.58
Marktkapitalisierung:
$6.46B
Einnahmen:
$569.61M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-7.788
EPS:
-13.6043
Netto-Cashflow:
$54.87M
1W Leistung:
-6.26%
1M Leistung:
-9.50%
6M Leistung:
+2.64%
1J Leistung:
+105.01%
1-Tages-Spanne:
$105.70
$113.46
1-Wochen-Bereich:
$105.70
$116.39
52-Wochen-Spanne:
$50.25
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
105.95 | 6.96B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals Inc (MIRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Market Sentiment - Benzinga España
Mirum Pharmaceuticals, Inc. Revenue Breakdown – BIVA:MIRM - TradingView
MIRM|Mirum Pharmaceuticals Inc|Price:113.030|Chg%:-1.330 - TradingKey
Mirum Pharmaceuticals, Inc. (MIRM) options chain - Yahoo Finance UK
Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails - Investing.com
Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: Exploring a 25.62% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Why (MIRM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Citizens reiterates Mirum Pharmaceuticals stock rating on revenue outlook By Investing.com - Investing.com Canada
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Arcutis Expands Board of Directors with Appointment of Chris Peetz - GlobeNewswire Inc.
MIRM5806400 Bond Risk Profile - TradingView
US604749AB7 Bond Coupon Profile — Rate & Payments - TradingView
US604749AB7 Bond Profile — Key Metrics - TradingView
US604749AC5 Bond Profile — Key Metrics - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P - GuruFocus
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing - Moomoo
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing - Moomoo
Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock - Investing.com
Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals outlines its liver disease focus as shares trade on Nasdaq - AD HOC NEWS
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating - marketscreener.com
Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM) - Stock Titan
Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM) - Stock Titan
Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio - Seeking Alpha
MIRMMirum Pharmaceuticals Inc Latest SEC Filings - Finviz
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum Pharmaceuticals SVP sells $326,520 in common stock By Investing.com - Investing.com South Africa
Form 4 Mirum Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Mirum Pharmaceuticals SVP sells $326,520 in common stock - Investing.com
Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock hits all-time high at 125.41 USD - Investing.com
J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125 - Moomoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib - Yahoo Finance
Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mirum Pharmaceuticals Inc-Aktie (MIRM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jul 06 '26 |
Sale |
122.27 |
20,000 |
2,445,382 |
194,309 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Jul 06 '26 |
Sale |
122.25 |
5,000 |
611,273 |
42,181 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):